Jump to content

Renovo plc: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Filling in 7 references using Reflinks, Script-assisted fixes per WP:TIES, MOS:NUM, MOS:CAPS, MOS:LINK
m Confirm {{Use dmy dates}} from 2013; WP:GenFixes & cleanup on
 
(32 intermediate revisions by 16 users not shown)
Line 1: Line 1:
{{Confusing|date=October 2019}}
{{EngvarB|date=September 2013}}
{{EngvarB|date=September 2013}}
{{Use dmy dates|date=September 2013}}
{{Use dmy dates|date=January 2024}}
{{Infobox Company
{{Infobox company
| company_name = Renovo Group plc
| name = Renovo Group plc
| logo =
| company_logo =
| company_type = [[Public limited company]]<br>({{lse|RNVO}})
| type = [[Public limited company]]
⚫
| foundation = October 2000
| company_slogan = |a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.
| defunct = {{End date and age|2011|5}}
⚫
foundation = October 2000
| location = [[Manchester]], United Kingdom
| location_city = [[Manchester]]
| location_country = [[United Kingdom]]
| key_people = [[Mark Ferguson (professor)|Mark Ferguson]] (CEO)
| key_people = Mark Ferguson <small>([[CEO]])</small>
| num_employees = |approx 110
| num_employees = 110
industry = [[Biotechnology]]
| industry = [[Biotechnology]]
| homepage = [http://www.renovo.com www.renovo.com]
| homepage = {{webarchive |url=https://web.archive.org/web/20130724115539/http://www.renovo.com/ |date=24 July 2013 }}
| revenue =
| revenue =
| net_income =
| net_income =
}}
}}


'''Renovo Group plc''' ({{lse|RNVO}}) is a [[biopharmaceutical]] company, which was founded in 1998 and is headquartered in [[Manchester]], United Kingdom. It works in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.<ref>[http://www.regenmednetwork.com/archive/january_2007_meeting/january_2007_meeting.html London Regenerative Medicine Network – January 2007 Meeting]{{dead link|date=September 2013}}</ref> Renovo does not currently have any marketed products. It aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe"<ref>http://www.renovo.com</ref> in approximately 2014. As of 2011, it employs 10 people, although it once employed over 100.<ref>[http://www.pharmatimes.com/article/11-03-04/Just_10_of_workforce_left_at_Renovo_after_Juvista_failure.aspx Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011)]. Pharmatimes.com.</ref>
'''Renovo Group plc''' was a [[biopharmaceutical]] company, which was founded in 1998 and was headquartered in [[Manchester]], United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.<ref>[http://www.regenmednetwork.com/archive/january_2007_meeting/january_2007_meeting.html London Regenerative Medicine Network – January 2007 Meeting] {{webarchive |url=https://web.archive.org/web/20070928140859/http://www.regenmednetwork.com/archive/january_2007_meeting/january_2007_meeting.html |date=28 September 2007 }}</ref> Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate [[Juvista]], all 100 of Renovo's staff were laid off in 2011.<ref>[http://www.manchestereveningnews.co.uk/business/business-news/renovo-group-founder-to-become-science-679234 Renovo Group founder to become Science Foundation Ireland's boss (9 January 2012)]. [[Manchester Evening News]].</ref><ref>[http://www.pharmatimes.com/article/11-03-04/Just_10_of_workforce_left_at_Renovo_after_Juvista_failure.aspx Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011)]. Pharmatimes.com.</ref><ref name="noworkers">{{cite web |url=http://www.pharmatimes.com/news/future_bleak_for_renovo_with_no_workers_or_products_980961 |last=Grogan |first=Kevin |title=Future bleak for Renovo with no workers or products |publisher=PharmaTimes |date=31 May 2001 |accessdate=14 December 2016}}</ref>


Although the company stopped all pharmaceutical development it continued as a financial provider. In August 2014, Renovo Group plc was renamed '''Inspired Capital plc'''.<ref>[https://www.insidermedia.com/insider/northwest/119202-rename-plan-renovo Rename Plan for Renovo (16 July 2014)]. InsiderMedia.com</ref><ref name="inland">{{cite web |url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=709788 |title=Company Overview of Inspired Capital plc |publisher=[[Bloomberg L.P.|Bloomberg]] |accessdate=14 December 2016}}</ref>
Renovo is listed on the [[London Stock Exchange]] and is a constituent of the [[FTSE Fledgling Index]].


==Products==
==Products==
Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two drugs in phase II clinical development, and numerous pre-clinical candidates.<ref>[http://www.renovo.com/content.asp?a_id=3 Renovo – Products]{{dead link|date=September 2013}}</ref>
Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two drugs in phase II clinical development, and numerous pre-clinical candidates.<ref>[http://www.renovo.com/content.asp?a_id=3 Renovo – Products] {{webarchive |url=https://web.archive.org/web/20100125033213/http://www.renovo.com/content.asp?a_id=3 |date=25 January 2010 }}</ref>


{| class="wikitable"
{| class="wikitable"
Line 30: Line 32:
|-
|-
| [[Juvista]]
| [[Juvista]]
| Failed<ref>[http://www.pharmatimes.com/article/11-03-04/Just_10_of_workforce_left_at_Renovo_after_Juvista_failure.aspx '&#39;Pharma Times'&#39; Just 10% of workforce left at Renovo after Juvista failure (4 March 2011)]. Pharmatimes.com.</ref>
| Failed<ref>[http://www.pharmatimes.com/article/11-03-04/Just_10_of_workforce_left_at_Renovo_after_Juvista_failure.aspx "Pharma Times" Just 10% of workforce left at Renovo after Juvista failure (4 March 2011)]. Pharmatimes.com.</ref>
| Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring through introduction of [[Recombinant DNA|recombinant]] [[TGFβ3]].
| Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring through introduction of [[Recombinant DNA|recombinant]] [[TGFβ3]].
|-
|-
| [[Adaprev]]
| Adaprev
| Halted<ref>Ashcroft, Jamie. (18 November 2011) [http://www.proactiveinvestors.co.uk/companies/news/35815/renovo-ends-adaprev-development--35815.html '&#39;ProactiveInvestors'&#39; – Renovo ends Adaprev development (18 November 2011)]. Proactiveinvestors.co.uk.</ref>
| Halted<ref>Ashcroft, Jamie. (18 November 2011) [http://www.proactiveinvestors.co.uk/companies/news/35815/renovo-ends-adaprev-development--35815.html "ProactiveInvestors" – Renovo ends Adaprev development (18 November 2011)]. Proactiveinvestors.co.uk.</ref>
| Injected at the time of surgery for the prevention and reduction of scarring and adhesions between the tendon and surrounding tissues following tendon repair.].
| Injected at the time of surgery for the prevention and reduction of scarring and adhesions between the tendon and surrounding tissues following tendon repair.].
|-
|-
| [[Prevascar]]
| Prevascar
| Halted<ref>Ashcroft, Jamie. (16 April 2012) [http://www.proactiveinvestors.co.uk/companies/news/41507/renovo-ends-prevascar-development-41507.html '&#39;ProactiveInvestor'&#39; Renovo ends Prevascar development (16 April 2012)]. Proactiveinvestors.co.uk.</ref>
| Halted<ref>Ashcroft, Jamie. (16 April 2012) [http://www.proactiveinvestors.co.uk/companies/news/41507/renovo-ends-prevascar-development-41507.html "ProactiveInvestor" Renovo ends Prevascar development (16 April 2012)]. Proactiveinvestors.co.uk.</ref>
| Injected to the wound margins around the time of surgery causes a reduction of scarring through suppression of [[TGFβ1]] and [[TGFβ2]].
| Injected to the wound margins around the time of surgery causes a reduction of scarring through suppression of [[TGFβ1]] and [[TGFβ2]].
|-
|-
| [[Juvidex]]
| Juvidex
|
|
| Renovo plans to partner Juvidex as a cosmetic ingredient for the improvement of skin appearance and to promote the healing of damaged skin.
| Renovo planned to partner Juvidex as a cosmetic ingredient for the improvement of skin appearance and to promote the healing of damaged skin.
|-
|-
| [[RN1005]]
| RN1005
| Phase I [[Clinical trial]]
| Phase I [[Clinical trial]]
| RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration.
| RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration.
Line 51: Line 53:


==References==
==References==
{{reflist}}
{{reflist|2}}


==External links==
==External links==
* [http://www.renovo.com www.renovo.com]
* {{Official website|http://www.renovo.com}}


{{Pharmaceutical industry in the United Kingdom}}
{{Pharmaceutical industry in the United Kingdom}}
{{Authority control}}


[[Category:Biotechnology companies of the United Kingdom]]
[[Category:Biotechnology companies of the United Kingdom]]
[[Category:Companies based in Manchester]]
[[Category:Companies based in Manchester]]
[[Category:Private equity portfolio companies]]
[[Category:Companies formerly listed on the London Stock Exchange]]
[[Category:Pharmaceutical companies established in 2000]]
[[Category:Biotechnology companies established in 2000]]
[[Category:2000 establishments in England]]
[[Category:2011 disestablishments in England]]
[[Category:Pharmaceutical companies disestablished in 2011]]
[[Category:Biotechnology companies disestablished in 2011]]




Latest revision as of 13:37, 23 January 2024

Renovo Group plc
Company typePublic limited company
IndustryBiotechnology
FoundedOctober 2000
DefunctMay 2011; 13 years ago (2011-05)
Headquarters
Manchester
,
United Kingdom
Key people
Mark Ferguson (CEO)
Number of employees
110
WebsiteArchived 24 July 2013 at the Wayback Machine

Renovo Group plc was a biopharmaceutical company, which was founded in 1998 and was headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.[1] Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate Juvista, all 100 of Renovo's staff were laid off in 2011.[2][3][4]

Although the company stopped all pharmaceutical development it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.[5][6]

Products

[edit]

Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two drugs in phase II clinical development, and numerous pre-clinical candidates.[7]

Drug Phase Action
Juvista Failed[8] Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring through introduction of recombinant TGFβ3.
Adaprev Halted[9] Injected at the time of surgery for the prevention and reduction of scarring and adhesions between the tendon and surrounding tissues following tendon repair.].
Prevascar Halted[10] Injected to the wound margins around the time of surgery causes a reduction of scarring through suppression of TGFβ1 and TGFβ2.
Juvidex Renovo planned to partner Juvidex as a cosmetic ingredient for the improvement of skin appearance and to promote the healing of damaged skin.
RN1005 Phase I Clinical trial RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration.

References

[edit]
  1. ^ London Regenerative Medicine Network – January 2007 Meeting Archived 28 September 2007 at the Wayback Machine
  2. ^ Renovo Group founder to become Science Foundation Ireland's boss (9 January 2012). Manchester Evening News.
  3. ^ Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
  4. ^ Grogan, Kevin (31 May 2001). "Future bleak for Renovo with no workers or products". PharmaTimes. Retrieved 14 December 2016.
  5. ^ Rename Plan for Renovo (16 July 2014). InsiderMedia.com
  6. ^ "Company Overview of Inspired Capital plc". Bloomberg. Retrieved 14 December 2016.
  7. ^ Renovo – Products Archived 25 January 2010 at the Wayback Machine
  8. ^ "Pharma Times" Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
  9. ^ Ashcroft, Jamie. (18 November 2011) "ProactiveInvestors" – Renovo ends Adaprev development (18 November 2011). Proactiveinvestors.co.uk.
  10. ^ Ashcroft, Jamie. (16 April 2012) "ProactiveInvestor" Renovo ends Prevascar development (16 April 2012). Proactiveinvestors.co.uk.
[edit]


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Renovo_plc&oldid=1198221994"